Larazotide

Larazotideis a peptide which is an orally active zonulin antagonist. Larazotide shows antiviral activity to varicella-zoster virus (VZV) with EC50s of 44.14 and 59.06 μM for strain OKA and 07-1, respectively. Larazotide can be used for the research of celiac disease and infection[1][2].

Research Areas >> Infection

Research Areas >> Inflammation/Immunology

Signaling Pathways >> Cytoskeleton >> Gap Junction Protein

Larazotide (1-100 μM; 5 d) affects Vero cell growth[1]. Larazotide (1-100 μM; 3 d) shows antiviral activity to varicella-zoster virus (VZV) with EC50s of 44.14 and 59.06 μM for strain OKA and 07-1, respectively[1]. Larazotide (1 and 3 mM; 72 h) inhibits cytokine-induced tight junction permeability in Caco-2 cells[2]. Larazotide (100 μM; 3 h) inhibits gliadin translocation across Caco-2 monolayers[2]. Larazotide (12.5 mM; 1 h) inhibits PTG-induced ZO-1 redistribution and actin cytoskeletal rearrangement in IEC6 cells[2]. Cell Cytotoxicity Assay[1] Cell Line: Vero cell line Concentration: 1-100 μM Incubation Time: 5 days Result: Inhibited Vero cell growth with an CC50 value of 82.5 μM.

Larazotide (250 μg; i.p. twice a week for 7 weeks) inhibits intestinal permeability in gluten-sensitive transgenic mice[1]. Animal Model: HLA-HCD4/DQ8 double transgenic mice[2] Dosage: 250 μg Administration: Intraperitoneal injection; 250 μg twice a week for 7 weeks Result: Improved barrier function parameters and reduced macrophage counts in the lamina propria to control levels.